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ABSTRACT 
Background: Diabetes Mellitus (DM) triggers an excessive reaction of free-radicals. It increases 
reactive oxygen species and reduces antioxidants status as well as the β cell damage. Clear kefir 
was used for DM therapies, however it limited biomolecular exploration of its bioactive roles. 
Research  aimed  to  investigate  the  effects  of  clear  kefir  on  the  biomolecular  nature  of  the 
glycemic status of T2DM in Bandung. 
    
Methods: The randomized pretest-posttest control group was conducted by 106 T2DM patients. 
Research was done in several hospitals in Bandung and Cimahi, West Java from 2012–2013. 
Samples were divided randomly into three groups: (1) T2DM with HbA1c < 7 was fed  a standard 
diet, supplemented with 200 ml/day of clear kefir, (2) T2DM with HbA1c > 7 fed standard diet 
and supplemented 200 ml/day by clear kefir, (3) T2DM with HbA1c was fed a standard diet as a 
control group. Dose response was obtained from a preeliminary vivo study, and then converted 
to  human  dosage  by  year  2011.  Intervention  was  effectively  done  for  30  days.  HbA1c  was 
measured by HPLC. Fasting blood glucose (FBG) and Postprandial blood glucose levels (PBG) 
were measured by enzymes levels. C Peptide and insulin were measured by Elisa. Data was 
analyzed  by  a  statictics  programme  by  significance  p<0,05.  Study  was  approved  by  ethic 
committee.  
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Results :  HbA1c was significantly reduced in delta level (p<0.01) and FBG (p<0.015) among 
kefir  groups. PBG was  not  significantly  reduced among  groups.  C-Peptide  was  significantly 
increased in delta level, except in control group (p<0.014). Insulin was reduced significantly, 
except in control group (p<0.003).   
 
Conclusions : Supplementation of clear kefir reduced blood glucose levels (HbA1c, FBG, PBG) 
and increased c-peptide. Clear kefir’s biomolecular mechanisms and chemistry characterization 
is a challenge for future studies.    
 
Keywords : Diabetes melitus, hyperglicemia, clear kefir, insulin, c peptide 
 
 
BACKGROUND: 
Diabetes mellitus is a metabolic disorder  which is characterized by hyperglycemic syndrome. 
The prevalence of type 2 diabetes increased yearly in  Indonesia.The number of patients was 
predicted to increase from 8.4 million in year 2000 to 21.3 million in year 2030 in this country 
[1].  Untreated, this disease will cause severe complications, such as: nephropathy, neurophaty 
and retinopaty. Consequently, it will  decrease the quality of long term human resources [2] 
Hyperglycemia caused  the pancreatic β cells to dysfunction [3].  Hyperglicemia enhanced 
the  formation  of  free  radicals  and  caused  oxidative  stress.  Free-radicals  increased  through 
various channels, such as: (1) non-enzymatic glycation (AGEs), (2) glucose auto-oxidation, (3) 
polyol pathway and protein kinase (PKC) [4, 5, 6, 7, 8].  As a result, it triggered an increase in 
free fatty acids, lipid peroxidation and proinflammatory cytokine production. It diminished the 
Langerhans organs, granule secretion of insulin,  decreased the β cells volume by 60% [9], and 
immune response. Oxidative stress reduced antioxidants capacity and lead to defective insulin 
secretion and gene expression. Furthermore, proinflammatory cytokines triggered and activated 
the  receptor  of  kinase  inhibitor  factors,  NFkB  and  stimulated  pancreatic  β  cell  damageto 
pancreatic β cell apoptosis by inhibiting the insulin signal [10, 11, 12, 13]. 
The β cells regeneration so far, is the newest insight in diabetic therapy. It can be applied 
through several approaches. The first is reduction of lipid peroxidation, and blood glucose. It will 
respectively inhibit proinfamatory cytokines  production.  Increased number  in  an endogenous 
antioxidant  enzyme  in  the  body,  may  decrease  oxidative  stress.  In  addition,  the  best  β  cell 
regeneration can be a systematic effort from inside his own body by  provision of the quality of 
nutrition intake such as protein. Protein can be enhanced to maintain and regenerate body cells. 
The available diabetes therapy has been unsuccessful in optimally controlling blood glucose 
levels [14].
  The use of insulin and medication are the most effective options, but it is difficult to 
be implemented  on an ongoing basis with respect to several reasons, such as: socioeconomic, 
residual and knwoledge barriers. Attempts on the induction of pancreatic β cell regeneration by 
using immunotherapy probiotics [15] are never reported elsewhere, but the results have been 
conflicting in relation to the application of therapy. Further studies are therefore important to 
ensure consistency in results.
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Clear kefir supplementation offers several bioactive compounds, such as exopolyssacharide, 
peptide,  antioxidant  and  immunomodulatory  properties  [16,  17,  18,  19]. 
    Kefir’s  peptide 
enhanced  the biological values and the digestibility of protein. It was also supported by Meier 
and Almatsier, that the best efforts for β cell regeneration is through a systematic effort from 
inside his own body.High quality nutrition intake, especially a high biological value of protein is 
very important, because protein will maintain and regenerate the body's cells [20, 21]. Kefir is 
also able to  activate the regulatory T (Treg) role which functions  to maintain homeostasis in 
Th1-Th2  responses.  The  mechanism  underlying  is  strengthened  by  the  immune  system  via 
normalized pro-inflammation cytokine production. Through their cytokine products, these cells 
enable suppression ofinflammatory reactions, and increased production of interleukin 10 (IL10) in 
pancreatic  cells. IL10 suppressed proinflammatory response and apoptosis [22].  
Kefir bening is a low-fat milk fermented by kefir grains. Kefir grains are symbiotic bacterias 
and yeast colonies. This fermentor containsmore than 35 beneficial healthy probiotic bacterias. It 
is also simple to produce and easy to be implemented in the household on an industrial scale. 
The research  aimed  to  investigate  clear kefir effects  on  the biomolecular aspects  of the 
glycemic  status  of  T2DM  in  Bandung.  It  was  measured  by  parameters  like  HBA1c,  Blood 
Glucose, Insulin and c-peptides among diabetes outpatients  in several hospitals in Bandung and 
Cimahi. 
 
METHOD AND MATERIALS: 
This research was randomized; control group pretest-posttest design [23] was conducted on 108 
diabetes mellitus out patients in several Hospitals in Bandung and Cimahi from  2012–2013. 
Samples  were  strictly  selected  by  inclusion  such  as:  T2DM  patients  based  on  the  doctor’s 
diagnosis,  and treated them with the last blood glucose level at about  < 200 mg/dL, HbA1c 
equivalent 6-8; no complications, illness, amples inclusion, or using same DM medication, were 
in the informed consent.  Samples were divided randomly into three groups: (1) T2DM with 
HbA1c < 7 fed a standard diet and supplemented 200 ml /day by clear kefir, (2) T2DM with 
HbA1c > 7 fed a standard diet and supplemented 200 ml /day by clear kefir, (3) T2DM with 
HbA1c fed a standard diet as control group. Kefir’s dose response was obtained and adapted from 
the  research  result  of  a  preelimary  in  vivo  study  in  2011.  Intervention  was  accomplished 
effectively during 30 days.  
Preparation  of  Mother  Kefir.  Standardize  the  milk  for  preparation  of  mother  kefir. 
Pasteurize skim milk at 90-95
o C for 15 min and cool to 18-22 
o C. Spread kefir grains at the 
bottom of a container (5-10 cm thick) and add pasteurized milk (20-30 times the volume of kefir 
grains). Ferment for 18-24 h, mixing 2-3 times. Kefir grains float to the surface. Filter out the 
kefir grains with a fine sieve; wash the grains with water and save for the next fermentation. 
Save the fermented milk for the next-step, which is inoculation. 
Preparation of Drinkable Clear Kefir. Blend fermented skim milk from above with 8-10 
times the volume of fresh, pasteurized, and untreated milk. Filter into bottles, close and fement 
for  1-3  days  at  18-22
  o  C  (room  temperature)  until  the  minimum  standards  for  lactic  acid 
bacterias (LAB) are achieved at 10
7 cfu/g. Another option is to mix the fermented milk with 
fresh milk at 1-5%; fermented at 18-25
 o C for 12-15 h until reaching pH 4.4-4.5, followed by Functional Foods in Health and Disease 2014; 4(8):340-348                                                            Page 343 of 348 
ripening in refrigerated storage tanks for 1-3
 o C  Kefir grains are commercial inoculum that are 
acquired from the House of Kefir Bening Semarang.   
Blood glucose consisted of fasting blood glucose (FBG), postprandial blood glucose (PBG)  
were measured by enzymatic methods. HbA1c was measured by HPLC. C-peptide and insulin 
were measured by Elisa. Statistical analysis presented of univariate data (mean, SD), bivariate 
(Kruskal Wallis, Mann Whitney with a significance level 0.05.)   
This  research  was  approved  by  the  Research  Ethics  Committee  for  Health  Research, 
Medicine  Faculty,  Diponegoro  University,  Semarang  and  Dr.  Kariadi  General  Hospital, 
Semarang. 
 
RESULTS: 
Research showed that fasting blood glucose (FBG) levels were decreased during study in both 
samples and the control groups. The best achievement reduction in fasting blood glucose levels 
were highest in group 2. It revealed that the average reduction is equal to -34.06 mg/dL and with 
a standard deviation about 55.12 mg/dL by group 2, and  group 1 reduced about -19.4286   
18.64 mg/dL.  The  statistical analysis indicated that there was a significant reduction in FBG 
levels in all three study groups ( p = 0.015 ). The table 1 presented research result Biomolecular 
Aspects of Glycemic Satatus of Type 2 Diabetes Mellitus (T2DM) Patients in Bandung, West 
Java 
 
Table 1. Biomolecular Aspects of Glycemic Satatus of Type 2 Diabetes Mellitus (T2DM) 
Patients in Bandung, West Java 
 
No  Variables 
Research groups 
Change 
of delta 
() 
p 
Group 1  Group 2  Group 3 (control) 
Pre-test 
Post-
test 
Change 
of delta 
() 
Pre-test 
Post-
test 
Change 
of delta 
() 
Pre-test 
Post-
test 
Change 
of delta 
() 
SD  SD  SD  SD  SD  SD  SD  SD  SD 
1 
FBG 
(mg/dL) 
144.74 
± 28.74 
125.31 
± 27.43 
(-19.43 
 18.64) 
188.94 
 71.40 
154.89 
 39.53 
(-34.06 
 
55.12) 
178.72 
 74.28 
175.81 
 70.79 
(-2.92  
66.59) 
0.015
* 
2 
PBG 
(mg/dL) 
213.60 
± 45.43 
156.97± 
41.90 
(-56.63 
 
42.1070) 
258.66 
 62.97 
195.80 
 73.87 
(-62.86  
 
57.44) 
262.25 
 61.35 
234.78 
 81.34 
(-28.47 
 
69.35) 
0.097 
3 
Insulin 
(pg/mL) 
3.76 ± 
6.0 
3.08 ± 
3.94 
(-1.68   
4.93) 
18.67  
8.24 
17.67  
8.08 
(-1.21  
 2.93) 
15.21  
9.65 
13.43  
9.83 
(-1.79  
2.58) 
0.003
* 
4 
c-peptide 
(pg/mL) 
0.86 ± 
0.80 
0.94 ± 
0.76 
0.68  
0.18  
0.68  
0.44 
0.75  
0.48 
0.07   
0.12 
0.12  
0.68 
0.11  
0.68 
(-0.016 
 0.06) 
0.014
* 
5 
HbA1c 
(pg/mL) 
6.56 ± 
0.32 
6.43 ± 
0.33 
(-0.13  
0.15) 
8.04  
0.92 
7.95  
0.79 
(-0.09  
0.24) 
8.20  
1.71 
8.20  
1.71 
0.001  
0.01 
0.001
* 
 
*Kruskal Wallis significancy by  p<0.05 
 
 All  groups  revealed  reduced  post  prandial  blood  glucose  (PBG),  however  the  higgest 
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showed a reduction of about -56.6286  42.1070 mg/dL. Statistical analysis showed that there 
was no significant increase among samples (intervention groups and control).  
Moreover, insulin levels decreased during study in both the samples and control groups. The 
best achievement insulin levels were slowest by group 2. It revealed an average reduction equal 
to -1,68  4.93 pg/mL, then it followed the reduction in average of about -1.21   2.93 pg/mL in 
group 2.  The  statistical analysis indicated that there was a significant reduction in FBG levels in 
all three study groups (p= 0.003).   
The best achievement in c-peptide levels were the increase by  group 1. Group 1had an 
average c-peptide level increase of about 0.68  0.18 pg/mL. It was followed by group 2 by 
about 0.07  0.12 pg/mL. In contrast, the control group (group 3) tended to reduce by -0.020.06 
pg/mL. Kefir has the potential to increase c-peptide levels because statistical analysis showed a 
significant difference of increase among groups.    
 HBA1c of research samples varied  among the groups, except of the control group. The 
control was gained with very small achievement in average about 0,001 + 0,001. Other groups 
were proven to reduce with achievement in group 1of about -0.130.15, and  Group  was also 
reduced by  about  -0.09   0.24.  Statistical  analysis respectively  found significant  difference 
among groups of samples (p> 0.05). 
 
Kefir is a healthy drink and hipocaloric. The results of the proximate analysis showed clear 
kefir levels of nutrients, such as: Energy obtained ranged 70.48 Kcal, fat content about 1.32 g. 
Trace elements improved at the 132 g calcium. Micronutrients were found, such as vitamin A, at 
about 220 IU. Table 2, shows a table of nutritional contents in kefir.  
  
                  Table 2. Nutrition contents of clear kefir serving in 100 ml 
 
No.  Nutrients  Content 
per 100 ml 
1  Energy (Kcal)  70.48 
2  Protein (g)  6.16 
3  Carbohydrate (g)  3.52 
4  Fat (g)  1.32 
5  Natrium (mg)  90.00 
6  Calcium (mg)  132.00 
7  Vitamin A (IU)  220.00 
8  Vitamin B (IU)  44.00 
 
 
DISCUSSION: 
This study has been demonstrateing that the supplementation of clear kefir 200 ml/day, for 30 
days, significantly affects blood glucose and c-petide levels.  Clear kefir reduced hyperglycemia 
and oxidative stress conditions. The mechanism underlying is probably caused by the reduction 
of oxidative stress. It played a critical role in decreasing the blood lipid peroxidation levels that 
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proinflammatory cytokine (IL1, IL6, TNF α ) production. Those cytokines inhibit insulin signals 
by activating the factor receptor kinase inhibitor, stimulating NFkB to pancreatic β cell damage 
and apoptosis [24].   Moreover,  insulin also increased the synthesis of protein used for the 
formation of new cells, including pancreatic β cells. Insulin has structurally and functionally 
similar molecules, including insulin-like growth factors, where its tertiary structure has a growth 
stimulant that forces the pancreatic β cells into regeneration. 
In addition, clear kefir also proved to effect pancreatic β cell regeneration. This mechanism 
underlying caused byits bioactive components, such as peptides and amino acids (AA). This 
peptide induced a highly biological protein and digestibility values, and as result, it continued to 
maintain and regenerate cells. Kefir enhances the usability of biological proteins and fats as well 
as the production of amino acids such as glutamine, arginine and nucleotides by the hydrolysis of 
enzymes  and  bacteria  hydrolysis.  The  nucleotide  is  basically  needed  for  establishing  and 
working arrangements of proteins in the small intestine, liver and lymph nodes, as well as for 
genetic mechanisms. This result correlated with a former finding in the vivo study where the 
result showed clear kefir supplementation.  It was systemically repairing and regenerating cells 
in the number of normal pancreatic β cells of Langerhans island during the intrevention process 
[24].  
Pancreatic β cell regeneration will lead to the restoration of pancreatic β cell mass, as a 
result of the restoration of physiology and insulin secretion. Other mechanisms can be done 
through preventative techniques against glucotoxicity and lipotoxicity, which empties into the 
occurrence  of  hyperglycemia,  and  gives  substances  act  to  reduce  the  occurrence  of 
hyperglycemia. 
 Clear  kefir  prevented  glucotoxiticity  and  lipotoxiticity,  and  reduced  the  occurrence  of 
hyperglycaemia. The mechanism underlying is accomplished via exopolissacharides. Bioactive 
exsopolyssacharides  (EPS)  have  been  activating  the  hormone  glucagon,  which  is  similar  to 
peptide 1 (GLP 1), gastric inhibitory peptide (GIP) and the enzyme adenylate cyclase through the 
cyclic adenosine monoposfat (cAMP), sensitization of Ca
2 ions and activation of protein kinase 
A, thus increasing insulin release from the pancreatic β cells. Then, the glucose can be utilized 
by the body tissues and cells.  Another mechanism underlying was probably EPS modulated of 
insulin  signaling  via  c-AMP  [25]  [26].  Increased  c-AMP  in  pancreatic  cells  revealed  and 
contributed to better insulin secretion from pancreatic β cells. 
 
Conclusions and Recommendations: Supplementation of clear kefir proved to reduce blood 
glucose (HbA1c, FBG, PBG) and increase c-peptide by 200 ml a day for 30 days.   
 
Competing interests: The authors declare that they have no competing interests with anyone or 
with any organizations. 
 
Abbreviations: 
DM, diabetes mellitus; T2DM, type 2 diabetes mellitus; HbA1c, , glycated haemoglobin; FBG, 
Fasting  Blood  Glucose;  PBG,  Postprandial  Blood  Glucose;  AGEs,  non-enzymatic 
glycated haemoglobin glycation; PKC, protein kinase; oxidative stress; NFKB, necrosis factor Functional Foods in Health and Disease 2014; 4(8):340-348                                                            Page 346 of 348 
kappa beta; ROS, reactive oxigen species; Treg, T regulator, IL10, Interleukin 10; Th1 Th2, T 
helper 1 and 2.  
Authors'  Contributions:    All  authors  contributed  to  this  study.  Judiono    designed  and 
conducted the study, performed the data analysis (including the statistical analysis) and drafted 
the manuscript. Suharyo Hadisaputro initiated the study, supervised and co-designed the entire 
study, and also co-revised and edited the manuscript in its entirety. Indranila KS performed and 
supervised blood specimen Elisa analysis. Bambang Cahyono and Meiny Suzery provided data 
antioxidants  analysis.  Asep  Iwan  Purnawan  performed  and  helped  to  enter  data  for  running 
statistical analysis. Yuliati Widiastuti performed assesing nutritional status, and clear kefir and 
dietetic intervention.    
 
Anknowledgement:  This  study  was  financially  supported  by  Indonesian  Danone  Institute 
Foundation.    The  views  expressed  herein  are  those  of  the  individual  authors,  and  do  not 
necessarily reflect those of Indonesian Danone Institute Foundation. We express our  gratitude to 
honourable  Professor  Dr.  Sukirman,  MPS  ID,  Professsor  RRJ.  Djokomoeljanto
(†),  Professor 
Endang Purwaningsih
(†), Dr. Yusron, SpPD, (an Internist of Military Army Hospital Cimahi) Dr. 
V. Dhian Rusnasari, SpPD (an Internist of The Bandung Saint Yosep Hospital), 
 who has given 
her support and ideas on the implementation of this study. Cebior Cq. GAKY Biomolecular 
Laboratory  University  of  Diponegoro  Semarang,  Integrated  Biomolecular  Laboratory  The 
Bandung Health Polytechnic, MOH R.I.  
 
REFERENCES: 
1.  WHO.  Prevalence  of  diabetes  worldwide.  2008.  http:  //www.who.int/  diabetes/facts 
/world_figures/en/  
2.  Hadisaputro, S., Setyawan, H. 2007. Faktor-Faktor yang berpengaruh terhadap kejadian 
Diabetes mellitus tipe 2, Naskah Lengkap Diabetes Melitus Ditinjau dari Berbagai Aspek 
Penyakit Dalam. Semarang: Badan Penerbit Universitas Diponegoro. 2007: p. 133-154 
3.  Brownlee,  Michael.  2004.  Banting  Lecture  2004.  The  Pathobiology  of  Diabetic 
Complications. A Unifying Mechanism. Diabetes, Vol. 54, June 2005. Page 1615- 1624 
4.  Betteridge, D.J. 2000.  What is oxidative stress? Metabolism Clinical and Experimental, 
(49), 2, Supplemen 1,  2000: p. 3-6 
5.  Ceriello,  A.  2000.  Oxidative  Stress  and  Glycemic  Regulation.  Metabolism  (49),2 
Supplement  2000: p. 27-29 
6.  Pfaffy,  2001.  Diabetic  Complications,  Hyperglicemia  &  Free  Radicals.  Biosciences 
Departement The University of Iowa. Iowa City, 2001. 52242 
7.  Djokomoeljanto.  RRJ.  2007.  Neuropati  Diabetik  dalam  Naskah  Lengkap  Diabetes 
Melitus  ditinjau  dari  berbagai  Aspek  penyakit  dalam  editor  Darmono,  dkk.  Badan 
Penerbit Universitas Diponegoro, 2007. Hal. 1-14 
8.  Soeyono, Slamet. 2005.  Resistensi insulin, Disfungsi sel β dan Peran antioksidan dalam 
terapi diabetes melitus. Prosiding Pekan Ilmiah Nasional Assosiasi Dietisien Indonesia, 
2005 Functional Foods in Health and Disease 2014; 4(8):340-348                                                            Page 347 of 348 
9.  American Diabetes Association (ADA). 2008. Diagnosis dan Clasification of Diabetes 
Melitus. Jurnal Diabetes Care, 2008. (31), 1, January 2008 
10. Maritim, A.C., R.A. Sanders., J.B. Watkins III. 2003  Diabetes, Oxidative Stress, and 
Antioxidants : A Review. J. Biochem Molecular Toxicology, Vol. 17, No.1. Page: 24-38 
11. Miriam Cnop,  Nils Welsh, Jean-Christophe Jonas, Anne Jo,  Sigurd Lenzen, and Decio 
L. Eizirik. 2005 Mechanisms of Pancreatic-Cell Death in Type 1 and Type 2 Diabetes. 
Many Differences, Few Similarities. Diabetes, Vol. 54, Supplement 2, December 2005. 
Page: S97-S-107 
12. Ortis, Fernanda.,  Alessandra K. Cardozo, Daisy Crispim, Joachim Sto¨ rling, Thomas 
Mandrup-Poulsen,and  De´  cio  L.  2006.  Eizirik.  Cytokine-Induced  Proapoptotic  Gene 
Expression in Insulin-Producing Cells Is Related to Rapid, .Sustained, and Nonoscillatory 
Nuclear Factor-kappa_B Activation. Molecular Endocrinology 2006(8):1867–1879 
13. Lee, Cathy C., Simin Liu. 2008 Role of Inflammatory Cytokines in Type 2 Diabetes. 
Review of Endocrinology, February 2008. Page: 19 -21 
14. Perkumpulan  Endokrinologi  Indonesia  (PERKENI).  2007.Konsensus  Pengelolaan 
Diabetes Melitus di Indonesia. Jakarta 2007a 
15. Hadisaputro,  S.,  Riwanto,Ig.,  Subagio,  H.W,  Judiono,  Laksono,B.,  Watuguly,  T. 
2008.Pendekatan Pengobatan Tradisional Untuk Tatalaksana Penyakit Infeksi HIV/AIDS 
dan Penyakit Degeneratif (Diabetes Mellitus dan Kanker Paru). Laporan Akhir Hibah 
Pasca Sarjana Universitas Diponegoro, 2008 
16. Brown, Amy C., Ana Valiere. 2004. Probiotics and Medical Nutrition Therapy,  Nutr 
Clin Care. 2004 ; 7(2): 56–68 
17. Sybesma,  W.F.,  Hugenholtz.  2004.  Food  fermentation  by  lactic  acid  bacteria  for 
prevention  of  cardiovascular.  Functional  foods,  cardiovascular  disease  and  diabetes. 
England: Woodhead Publishing Limited, 2004: page: 448-469 
18. Khazrai,  Y.M.,  S  Manfrini  and  P.  Pozzilli.  2004.  Diet  and  diabetes:  prevention  and 
control. Functional foods, cardiovascular disease and diabetes. England: Woodhead  
19. Virtanen, S.M. 2004.Nutritional risk factors in the development of type 1 and type 2 
diabetes.  Functional  foods,  cardiovascular  disease  and  diabetes.  England:  Woodhead 
Publishing Limited, 2004: page: 142-148 
20. Almatsier,  Sunita.  2003.  Prinsip  Dasar  Ilmu  Gizi,  Gramedia  Pustaka  Utama.  Jakarta, 
2003 
21. Meier, JJ. 2008. Beta cell mass in diabetes: a realistic therapeutic target. Diabetologia 
(2008) 51: 703-713 
22. Susetia-Totoprajogo, Ongko. 2010. Probiotic and Gut Immune System. Makalah Malang 
Nutrition Up Date, Mei 2010 
23. Hulley,  Stephen  B.,  Cumming,  Steven  R.,  Grady,  Deborah.  2007    Designing  a 
Randomized  Blinded  Trial,  Chapter  10.  Designing  Clinical  Research,  3rd  Edition. 
Philadelphia, USA: Lippincott Williams & Wilkins. Page: 147-161 
24. Judiono, RRJ. Djokomoeljanto, Suharyo Hadisaputro.  Biomolecular Aspects of Clear 
Kefir antidiabetic Potentials. IJFNPH 
http://www.worldsustainable.org/index.php/component/docman/cat_view/127-Functional Foods in Health and Disease 2014; 4(8):340-348                                                            Page 348 of 348 
international-journal-of-food-nutrition-a-public-health/175-ijfnph-v5-nos123-
2012?limit=5&order=date&dir=DESC&start=10 
25. Takeda,  Kiyoshi,    Shizuo  Akira.  2004.  TLR  signaling  pathways.  Seminars  in 
Immunology 16 (2004). Page: 3–9 
26. Maeda,  Hiroaki.,  Xia  Zhu,  Kazunobu  Omura,  Shiho  Suzuki,  Shinichi  Kitamura. 
2004.Effects of an exopolysaccharide (kefiran) on lipids, blood pressure, blood glucose, 
and constipation. BioFactors  Vol. 22, Issue 1-4 ( 2004). Page: 197-200 
 